Riskpilot← Back to searchSign inGet full accessFARMALOGG AS
ASActiveOrg 896031082Slemdalsveien 1, 0369 OsloOther software publishing · NACE 5829Est. 20105 employees
Revenue 2024
NOK 17,8M
+6% vs 2023
EBITDA margin
23.0%
-23% vs 2023
Equity ratio
61.4%
Financial strength
Net profit 2024
NOK 3,6M
-18% vs 2023
| Revenue | NOK 17,8M | +6% |
| EBITDA | NOK 4,1M | -23% |
| Net profit | NOK 3,6M | -18% |
| Total assets | NOK 12,8M | +5% |
| Equity | NOK 7,9M | +26% |
| Employees | 5 | — |
Legal name
FARMALOGG AS
Org number
896031082
Legal form
Aksjeselskap
NACE code
5829 · Other software publishing
Founded
20. oktober 2010
Share capital
NOK 200 000
Employees
5 (FTE)
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
To styremedlemmer i fellesskap. Styrets leder alene.
Company purpose
Tjenesteproduksjon overfor apotek og legemiddelområdet, samt annen næringsvirksomhet.
Address
Slemdalsveien 1, 0369 Oslo
Email
farmalogg@apotek.no
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Revenue | 14 277 | 15 373 | 15 902 | 16 858 | 17 796 |
| Staff expenses | −4 690 | −5 239 | −5 541 | −5 360 | −6 281 |
| EBITDA | 3 707 | 4 923 | 4 940 | 5 338 | 4 091 |
| Depreciation & amort. | −377 | −145 | −13 | −17 | −17 |
| EBIT | 3 330 | 4 779 | 4 927 | 5 321 | 4 074 |
| Net financials | 19 | 14 | 136 | 400 | 592 |
| Profit before tax | 3 350 | 4 793 | 5 063 | 5 722 | 4 666 |
| Tax | 688 | 1 049 | 1 114 | 1 259 | 1 026 |
| Net profit | 2 662 | 3 744 | 3 949 | 4 463 | 3 640 |
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Total assets | 7 565 | 9 463 | 9 837 | 12 132 | 12 783 |
| Equity | 2 740 | 2 740 | 4 250 | 6 213 | 7 853 |
| Long-term debt | 0 | 0 | 0 | 0 | 0 |
| Short-term debt | 4 812 | 6 723 | 5 587 | 5 920 | 4 930 |
| Total debt | 4 825 | 6 723 | 5 587 | 5 920 | 4 930 |
EBITDA margin
23.0%
This company
15.8%
Market median
+46% vs market
20202024
Equity ratio
61.4%
This company
38.2%
Market median
+61% vs market
20202024
Return on equity
46.4%
This company
18.4%
Market median
+152% vs market
20202024
Net profit margin
20.5%
This company
8.1%
Market median
+153% vs market
20202024
Asset turnover
1.39×
This company
1.12×
Market median
+24% vs market
20202024
Debt / equity
0.63×
This company
0.62×
Market median
+2% vs market
20202024
- Annual report 2024Filed via Brønnøysundsregistrene · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Brønnøysundsregistrene · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Brønnøysundsregistrene · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Brønnøysundsregistrene · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Brønnøysundsregistrene · Period 2020-01-01 – 2020-12-31
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
PV Chief Executive Officer | Chief Executive Officer | 2011 |
| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
| Board of Directors | 2022 | |
| Chairman | 2022 | |
| Former (2) | ||
| Board of Directors | 2022 – 2024 | |
| Chairman | 2019 – 2022 | |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
| Company | 100% | 100% | 2024 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
Apotekforeningen
FARMALOGG AS Board members of FARMALOGG AS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Per Viksmo | Chief Executive Officer | 0 companies |
| Steffan Møinichen Bollandsås Antonsen | Board of Directors | 0 companies |
| Anne-Lise Härter | Board of Directors | 0 companies |
| Leif Ola Rød | Chairman | 0 companies |
| Oddbjørn Tysnes | Chairman | 0 companies |